<DOC>
	<DOC>NCT00303485</DOC>
	<brief_summary>This study will determine the rapidity of suppression of the bone resorption marker sCTX in post-menopausal women with osteoporosis.Other bone turnover markers will also be evaluated. Patients will be randomised to either monthly Boniva 150mg or placebo, in combination with vitamin D and calcium supplementation. The anticipated time on study treatment is approximately 7 months, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>women who have been newly diagnosed with postmenopausal osteoporosis, requiring treatment; naive to bisphosphonate treatment,or had bisphosphonate treatment for a maximum of 3 months, at least 5 years before screening. patients on hormone replacement therapy (HRT) within the last 3 months; patients on other osteoporosis medication within the last 3 months; sCTX below lower limit, or above 3 times the upper limit, of normal premenopausal level; hypersensitivity to any component of ibandronate; contraindication for calcium or vitamin D therapy; history of major gastrointestinal upset; malignant disease diagnosed within the previous 10 years (except resected basal cell cancer).</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>